Cilt 1 Sağlık Bilimleri

PALİPERİDON TEDAVİSİ BAŞLANMASI İLE İLİŞKİLİ AKUT DİSTONİ: İKİ VAKA BİLDİRİMİ

Yakup Albayrak, Cuneyt Unsal

ÖZ

Paliperidon şizofreni tedavisinde kullanılan ikinci kuşak bir antipsikotiktir. Risperidonun aktif metabolitidir ve neredeyse dopamin D2 reseptörü ve serotonin 5-HT2 reseptörü için risperidon ile aynı yüksek afiniteyi gösterir. Literatürde paliperidon tedavisi ve akut distoni arasındaki ilişki ile ilgili bilgiler kısıtlıdır. Bu yazıda, paliperidon tedavisine başlangıç sonrasında akut distoni görülen iki hastayı bildirdik. Paliperidonun bazı hassas hastalarda güçlü bir D2 reseptör blokeri gibi etki edebileceği ve akut distoninin paliperidonun düşük dozla başlangıç tedavisinde dahi erken bir yan etki olarak akılda tutulması gerektiğini düşünmekteyiz.

ABSTRACT

Paliperidone is a second- generation antipsychotic which is used in the treatment of schizophrenia . It is an active metabolite of risperidone and shows almost the same high affinity for dopamine D2 receptor and serotonin 5-HT2 receptor .The data about the association between acute dystonia and paliperidone treatment is restricted in literature. In this paper, we reported two cases who devoloped acute dystonia after initiating of paliperidone treatment. We suggest that paliperidone might acts a potential dopamine D2 receptor blocking agent in some vulnerable patients and acute dystonia should kept in mind as an early side effect of paliperidone even initating with low doses.


Kaynakça
1. Mazurek MF, Rosebush PI. Acute drug induced dystonia. Eds Factor SA, Lang AE, Weiner
WJ. Drug Induced Movement Disorders,second edition, Blackwell Publishing,2005, Oxford,
UK.
2. Matson JL, Rivet TT, Fodstad JC. Atypical Antipsychotic Adjustments and Side-Effects
over Time in Adults with Intellectual Disability Tardive Dyskinesia, and Akathisia, J Dev
Phys Disabil 2010; 22:447- 461.
3. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or
cardiometabolic risk?, Acta Psychiatr Scand. 2009;119(3):171-9.
4. Cerovecki A, Musil R, Klimke A, Seemüller F, Haen E, Schennach R, Kühn KU, Volz HP,
Riedel M. Withdrawal symptoms and rebound syndromes associated with switching and
discontinuing atypical antipsychotics: theoretical background and practical recommendation,
CNS Drugs. 2013 ;27(7):545-72.
5. Tatara A, Shimizu S, Shin N, Sato M, Sugiuchi T, Imaki J, Ohno Y. Modulation of
antipsychotic-induced extrapyramidal side effects by medications for mood disorders, Prog
Neuropsychopharmacol Biol Psychiatry 2012; 7;38(2):252-9.
6. Suzuki H, Gen K, Otomo M, Inoue Y, Hibino H, Mikami A. Study of the efficacy and
safety of switching from risperidone to paliperidone in elderly patients with schizophrenia.
Matsumoto H, Mikami K, Psychiatry Clin Neurosci. 2013;67(2):76-82.
7. Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M.
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with
schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol
2007; 27:6–14.
8. Jesić MP, Jesić A, Filipović JB, Zivanović O. Extrapyramidal syndromes caused by
antipsychotics. Med Pregl. 2012;65(11-12):521-6
9. Rasimas JJ, Liebelt EL. Adverse Effects and Toxicity of the Atypical Antipsychotics: What
is Important for the Pediatric Emergency Medicine Practitioner, Clin Pediatr Emerg Med.
2012 1;13(4):300-310.
10. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission
tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated
with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen
Psychiatry. 1992;49(7):538-44.
11. Janssen, L.P: Paliperidone drug information. Titusville NJ, Janssen, L.P. 2006
12. Lapid MI, Cunningham JL, Hugo Z, Kung S, Acute dystonia associated with paliperidone
overdose. Psychosomatics. 2011;52(3):291-4.
13. Yanartaş Ö, Yılmaz Y, Saygılı I, Zincir S B, Semiz Ü B. Two cases of tardive dyskinesia
associated with the use of paliperidone ER and their management Klinik Psikofarmakoloji
Bülteni 2011; 21.
14. Keepers GA, Casey DE. Prediction of neuroleptic-induced dystonia. J Clin
Psychopharmacol. 1987;7(5):342-5.
15. Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M,
Okubo Y, Suhara T. Dose-finding study of paliperidone ER based on striatal and extrastriatal
dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl).
2008;197(2):229-35
Corresponding Author:
*Dr. Cuneyt UNSAL
Department of Psychiatry, School of Medicine,
Namik Kemal University, Tekirdag, Turkey. 59100
e-mail: drcunsal@gmail.com
Tel: +90 282 250 51 58 - Fax: +90 282 250 99 50
Ayrıntılar
Konular
Diğer ID
Dergi Bölümü Makaleler
Yazarlar

Yazar: Arş. Gör. Gamze Yıldız ŞEREN
Namık Kemal Üniversitesi, İİBF, Kamu Maliyesi Bölümü
e-posta: gyseren@nku.edu.tr

Yazar: Arş. Gör. Emin DEDEBEK
Namık Kemal Üniversitesi, İİBF, Maliye Bölümü
e-posta: ededebek@nku.edu.tr

Bir cevap yazın

E-posta hesabınız yayımlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir